AB-101 (Artiva Biotherapeutics)

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameAB-101 (Artiva Biotherapeutics)
Drug Alias NameAlloNKAB-101GCC4001GCC-4001
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGC Cell Corp
China Registration ClassN/A

Develop Information

Active CompaniesAffimed NvArtiva Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[7] 
Inactive IndicationsLymphoma, T-Cell, PeripheralHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A